文献速递冠心病外科

基于替格瑞洛的抗血小板方案用于冠状动脉旁路移植术患者的荟萃分析

Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials.
PubMed 文献 · Eur J Cardiothorac Surg · 2020-01-01

该荟萃分析纳入5项随机对照试验共3996例CABG患者,比较基于替格瑞洛方案与对照抗血小板方案。中位随访12个月,替格瑞洛方案降低全因死亡、心源性死亡和主要不良心脏事件风险,不增加出血风险,心肌梗死、卒中和出血风险无差异。

要点

  • 替格瑞洛方案降低CABG患者全因死亡、心源性死亡和MACE风险。
  • 替格瑞洛方案不增加出血风险,心肌梗死和卒中风险无差异。
  • 获益在主要纳入急性冠脉综合征患者的研究中更显著。

核心结论

  • 在CABG患者中,基于替格瑞洛的抗血小板方案较阿司匹林单药或阿司匹林联合氯吡格雷降低死亡率和主要不良心脏事件,且不增加出血风险。
  • 替格瑞洛方案的获益在主要纳入急性冠脉综合征患者的研究中更相关。

研究设计与样本

  • 研究为荟萃分析,检索截至2019年4月1日的科学数据库,纳入随机分配CABG患者至替格瑞洛方案或对照抗血小板方案的试验。
  • 共纳入5项试验,3996例患者,其中2002例分配至替格瑞洛方案,1994例分配至对照方案,中位随访12个月。
  • 对照抗血小板方案包括阿司匹林或氯吡格雷或两者联合。
  • 研究注册于PROSPERO,注册号CRD42019122192。

主要发现

  • 与对照相比,替格瑞洛方案降低全因死亡风险[0.61 (0.43-0.87); P = 0.007]。
  • 替格瑞洛方案降低心源性死亡风险[0.58 (0.39-0.86); P = 0.007]。
  • 替格瑞洛方案降低主要不良心脏事件风险[0.79 (0.63-0.98); P = 0.03]。
  • 心肌梗死风险[0.76 (0.50-1.18); P = 0.22]、卒中风险[0.99 (0.56-1.78); P = 0.98]和出血风险[1.04 (0.95-1.14); P = 0.41]无差异。
  • 主要结局存在治疗效应修饰,与主要纳入急性冠脉综合征患者的研究相关(交互作用P = 0.038)。

临床怎么用

  • 对于CABG术后患者,可考虑基于替格瑞洛的抗血小板方案以降低死亡和主要不良心脏事件风险。
  • 在主要纳入急性冠脉综合征患者的CABG人群中,替格瑞洛方案的获益可能更明显。
  • 需在针对该亚组患者且以临床结局为终点的随机试验中进一步确认这些发现。

局限性

  • 结论需在聚焦急性冠脉综合征亚组且以临床结局为终点的随机试验中进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The optimal antiplatelet strategy in patients undergoing CABG remains unclear. This is the first meta-analysis investigating the clinical outcomes associated with ticagrelor-based antiplatelet regimens in patients receiving CABG. METHODS: Relevant scientific databases were searched for studies investigating antiplatelet regimens after CABG from inception until April 1, 2019. Studies which randomly assigned CABG patients to either ticagrelor-based or control antiplatelet regimens were eligible. The primary outcome of this analysis was all-cause death. The main secondary outcome was MI. Other outcomes of interest were cardiac death, major adverse cardiac events, stroke and bleeding. This study is registered with PROSPERO, number CRD42019122192. RESULTS: Five trials comprising 3996 patients (2002 assigned to ticagrelor-based and 1994 to control antiplatelet regimens) were eligible for quantitative synthesis. The median follow-up was 12 months. Control antiplatelet regimens consisted of either aspirin or clopidogrel or both. As compared to control, ticagrelor-based regimens reduced the risk of all-cause death [0.61 (0.43-0.87); P = 0.007], cardiac death [0.58 (0.39-0.86); P = 0.007] and major adverse cardiac events [0.79 (0.63-0.98); P = 0.03], without difference in the risk of MI [0.76 (0.50-1.18); P = 0.22], stroke [0.99 (0.56-1.78); P = 0.98] or bleeding [1.04 (0.95-1.14); P = 0.41]. There was a treatment effect modification for the primary outcome associated with trials enrolling predominantly patients with acute coronary syndrome (P for interaction = 0.038). CONCLUSIONS: In patients receiving CABG, ticagrelor-based regimens reduce mortality and major adverse cardiac events without excess bleeding risk as compared with aspirin monotherapy or the combination of aspirin and clopidogrel. The benefit of ticagrelor-based regimens is more relevant in those studies enrolling predominantly patients with acute coronary syndrome. These findings require further confirmation in randomized trials focused on this subset of patients and powered for clinical outcomes.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. von Scheidt M, Bongiovanni D, Tebbe U, et al. Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials. Eur J Cardiothorac Surg. 2020. PMID: 31566205. doi:10.1093/ejcts/ezz260

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。